Yahoo Finance

Cristcot Announces Positive Phase 3 Results for Novel Hydrocortisone Acetate Suppository Administered with the Sephure® Suppository Applicator for the Treatment of Ulcerative ...

CONCORD, Mass., Jan. 9, 2025 /PRNewswire/ -- Cristcot, a clinical-stage pharmaceutical company advancing innovative therapies for gastrointestinal diseases, today announced positive topline results ...
Business Insider

Cristcot to Present Oral Abstract at 2026 Digestive Disease Week (DDW)

AUSTIN, Texas, April 29, 2026 (GLOBE NEWSWIRE) -- Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the Company will ...
Yahoo Finance

Cristcot Announces FDA Acceptance of NDA for Next-Generation Hydrocortisone Acetate (ngHCA) for Treatment of Ulcerative Colitis (UC) of the Rectum

AUSTIN, Texas, April 21, 2026 (GLOBE NEWSWIRE)-- Cristcot, a clinical-stage pharmaceutical company advancing targeted therapies for gastrointestinal diseases, today announced that the U.S. Food and ...
PharmiWeb

Cristcot Appoints Jenny Gizzi as Chief Administrative Officer

CONCORD, Mass., May 19, 2025 – Cristcot, a clinical-stage pharmaceutical company advancing innovative therapies for gastrointestinal diseases, today announced the appointment of Jenny Gizzi as Chief ...
Medindia

Cristcot to Present Data on Novel Ulcerative Colitis Treatment at the American College of Gastroenterology 2025 Annual Meeting

CESSA Phase 3 Clinical Trial Results Earn ACG Presidential Poster Distinction Among Nearly 6,000 Abstracts AUSTIN, Texas, Oct. 26, 2025 /PRNewswire/ -- Cristcot, a clinical-stage pharmaceutical ...
Mena FN

Cristcot Highlights Engagement With GI Community At 2025 GI Reconnect Annual Meeting

CONCORD, Mass., June 24, 2025 /PRNewswire/ -- Cristcot , a clinical-stage pharmaceutical company advancing innovative therapies for gastrointestinal diseases, participated in the 5 th annual GI ...
MarketWatch

Cristcot Announces Positive Phase 3 Results for Novel Hydrocortisone Acetate Suppository Administered with the Sephure(R) Suppository Applicator for the Treatment of Ulcerative ...

Pivotal Phase 3 Data Met Pre-defined Outcomes - Achieving a Clinical Response by Day 15 and Clinical Remission by Day 29 On Track for NDA Submission in Q1 2025 CONCORD, Mass., Jan. 9, 2025 /PRNewswire ...
Mena FN

Cristcot Announces FDA Acceptance Of NDA For Next-Generation Hydrocortisone Acetate (Nghca) For Treatment Of Ulcerative Colitis (UC) Of The Rectum

-- Prescription Drug User Fee Act (PDUFA) target date of October 2026 -- -- Submission supported by CESSA Phase 3 trial results demonstrating statistically significant rates of clinical remission in ...
manilatimes

Cristcot to Present Oral Abstract at 2026 Digestive Disease Week (DDW)

Oral presentation on the impact of concomitant steroid use in ulcerative colitis (UC) scheduled for May 5, 2026, at 9:30am CDT AUSTIN, Texas, April 29, 2026 (GLOBE NEWSWIRE)-- Cristcot, a ...
KOIN 6

Cristcot Announces Positive Phase 3 Results for Novel Hydrocortisone Acetate Suppository Administered with the Sephure® Suppository Applicator for the Treatment of Ulcerative ...

Pivotal Phase 3 Data Met Pre-defined Outcomes - Achieving a Clinical Response by Day 15 and Clinical Remission by Day 29 On Track for NDA Submission in Q1 2025 CONCORD, Mass., Jan. 9, 2025 /PRNewswire ...